Back to Browse Journals » International Journal of Women's Health » Volume 1

Safety, efficacy, actions, and patient acceptability of drospirenone/ethinyl estradiol contraceptive pills in the treatment of premenstrual dysphoric disorder

Authors Lesley L Breech, Paula K Braverman

Published Date August 2009 Volume 2009:1 Pages 85—95

DOI http://dx.doi.org/10.2147/IJWH.S4338

Published 5 August 2009

Lesley L Breech, Paula K Braverman

Division of Adolescent Medicine, Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA

Abstract: Premenstrual dysphoric disorder (PMDD) is estimated to affect 3%–8% of reproductive age women. Multiple therapeutic modalities have been evaluated with varying efficacy for the associated somatic and mood symptoms. The majority of older studies had shown that oral contraceptive pills (OCs) were most effective for the physical symptoms. However, newer OCs containing a novel progestin, drospirenone, have shown promise in alleviating both the somatic and affective/behavioral symptoms. This progestin, which is a derivative of spironolactone, has both antimineralocorticoid and antiandrogenic activity. A 24/4 formulation containing 20 µg of ethinyl estradiol has been found effective in randomized double-blind placebo-controlled trials utilizing established scales documenting symptoms associated with PMDD. Multiple studies have shown that drospirenone-containing OCs are safe without evidence of clinically adverse effects on carbohydrate metabolism, lipids, blood pressure, weight, serum potassium or increased thrombotic events compared to other low dose OCs. In addition, significant improvements have been demonstrated in acne, hirsutism, and fluid retention symptoms. Several open label studies demonstrated good patient compliance and reported satisfaction with the method. Because of the significant placebo effect demonstrated in the blinded placebo-controlled trials, additional large randomized placebo-controlled trials are needed to confirm the efficacy of the drospirenone OCs in the treatment of PMDD. However, this OC formulation appears to be a promising therapeutic modality.

Keywords: drospirenone, premenstrual dysphoric disorder, premenstrual syndrome, oral contraceptive pill

General overview

Premenstrual dysphoric disorder (PMDD) is estimated to affect 3%–8% of reproductive age women causing symptoms that adversely affect their quality of life. Previous studies with birth control pills have shown that they were most effective for the physical symptoms associated with PMDD. However, a newer formulation of birth control pills which contains the progestin drospirenone, has shown promise in being effective for both the mood and physical symptoms. Birth control pills containing this formulation do not have more side effects than other birth control pills, and have been shown to improve acne, fluid retention symptoms, and excess body hair. Although more studies are needed to confirm these results, this birth control pill appears to be a promising therapeutic modality for women with PMDD.

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Targeted delivery of brain-derived neurotrophic factor for the treatment of blindness and deafness

Khalin I, Alyautdin R, Kocherga G, Bakar MA

International Journal of Nanomedicine 2015, 10:3245-3267

Published Date: 30 April 2015

Chloramphenicol encapsulated in poly-ε-caprolactone–pluronic composite: nanoparticles for treatment of MRSA-infected burn wounds

Kalita S, Devi B, Kandimalla R, Sharma KK, Sharma A, Kalita K, Kataki AC, Kotoky J

International Journal of Nanomedicine 2015, 10:2971-2984

Published Date: 15 April 2015

The significance of combining VEGFA, FLT1, and KDR expressions in colon cancer patient prognosis and predicting response to bevacizumab

Zhang SD, McCrudden CM, Meng C, Lin Y, Kwok HF

OncoTargets and Therapy 2015, 8:835-843

Published Date: 15 April 2015

Design and in vivo evaluation of oxycodone once-a-day controlled-release tablets

Kim JY, Lee SH, Park CW, Rhee YS, Kim DW, Park J, Lee M, Seo JW, Park ES

Drug Design, Development and Therapy 2015, 9:695-706

Published Date: 30 January 2015

A pilot randomized controlled trial using EEG-based brain–computer interface training for a Chinese-speaking group of healthy elderly

Lee TS, Quek SY, Goh SJA, Phillips R, Guan C, Cheung YB, Feng L, Wang CC, Chin ZY, Zhang H, Lee J, Ng TP, Krishnan KRR

Clinical Interventions in Aging 2015, 10:217-227

Published Date: 9 January 2015

Supramolecular micellar nanoaggregates based on a novel chitosan/vitamin E succinate copolymer for paclitaxel selective delivery

Lian H, Sun J, Yu YP, Liu YH, Cao W, Wang YJ, Sun YH, Wang SL, He ZG

International Journal of Nanomedicine 2011, 6:3323-3334

Published Date: 12 December 2011

Tinidazole in the treatment of bacterial vaginosis

Nicola R Armstrong, Janet D Wilson

International Journal of Women's Health 2009, 1:59-65

Published Date: 25 June 2009